Hospira 4Q Revenues: $946.1 million (+34%) 4Q Earnings:  $76.1 million (+61%) FY Revenues: $3.4 billion (+28%) FY Earnings: $136.8 million (-43%) Comments: Sales in the quarter and FY excluding Mayne Pharma sales grew 8% and 4%, respectively. Injectable pharmaceutical contract manufacturing revenues dropped 14% to $37.4 million in 4Q07 and 19% to $149 million for FY07. R&D expenses in 4Q were down 2% to $53.8 million and acquired in-process R&D expenses were $3.2 million,...